Individuals with MCT8 deficiency have been identified by targeted sequencing of SLC16A2, on the X chromosome, in selected individuals (usually male) with clinical and biochemical characteristics, or by exome sequencing strategies (including specific gene panels, e.g. global developmental delay, hypotonia, spasticity, and seizures). Here, SLC16A2 is linked to Global developmental delay.